Comparison of two kind of drug oral and subcutaneous in prevention of deep vein ?thrombosis in patients admitted to intensive care unit

Comparison of Enoxaparin versus oral Rivaroxaban in prevention of deep vein ?thrombosis in patients admitted to intensive care unit

Status

Active, not recruiting

Phases

Phase 3

Study type

Interventional

Source

IRCT

Registry ID

IRCT20141209020258N140

Enrollment

Registered

2020-04-08

Start date

2018-10-23

Completion date

Unknown

Last updated

2020-05-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Thromboembolism. Embolism and thrombosis of unspecified artery

Interventions

Intervention 1: Intervention group: We treat patients with 15 milligram Rivaroxaban tablets daily orally or oral gavage until they have the order to get out of bed. Intervention 2: Control group: We

Eligibility

Sex/Gender

All

Age

18 Years to 60 Years

Inclusion criteria

Inclusion criteria: Ages 18 to 60 years Possibility to gavage or start oral feeding Glomerular filtration above 50% Patients hospitalized in intensive care units

Exclusion criteria

Exclusion criteria: Contraindications to anti-coagulant Allergy to Rivaroxaban

Design outcomes

Primary

Measure	Time frame
Incidence of thromboembolism. Timepoint: After the end of treatment. Method of measurement: Physical examination.	—

Countries

Iran (Islamic Republic of)

Contacts

Public ContactDr Behnam Mahmodie

Arak University of Medical Sciences

mahmodie@arakmu.ac.ir+98 86 3222 2003

Outcome results

None listed

Source: IRCT (via WHO ICTRP) · Data processed: Feb 4, 2026